Clinical Study Summaries

BD Vialon™ Biomaterial is a proprietary biomaterial designed exclusively by BD for vascular access. By softening (up to 70% while in the vessel) and conforming to the vessel, in conjunction with its ultra-smooth microsurface, BD Vialon biomaterial reduces the chance of irritation to the vessel wall. This, in turn, reduces the incidence of phlebitis, a major complication of IV therapy.

With over a decade of research, BD Vialon biomaterial is clinically proven to enhance your patient and clinical outcomes.

To receive a complimentary copy of the article, please contact your local BD Sales Consultant at 1-800-219-7174 or Customer Service at 1-888-237-2762.

• Risk Factors for Infusion-related Phlebitis with Small Peripheral Venous Catheters (Order No. 543)
• Infusion Thrombophlebitis: A Prospective Comparison of 645 Vialon and Teflon Cannulae in Anaesthetic and Postoperative Use (Order No. 528)
• Complications of Intravenous Therapy: A Randomized Prospective Study - Vialon vs. Teflon (Order No. 532)
• Infiltration During Intravenous Therapy in Neonates: Comparison of Teflon and Vialon Catheters (Order No. 550)
• Effect of Type of Material on Thrombophlebitis Risk with Peripheral Venous Catheters (Not Available)

• Studied the influence of 23 factors on the occurrence of phlebitis.
• Involved 1,054 catheter insertions.
• Compared FEP-Teflon® with PEU-Vialon™.
• Analysis included stepwise logistic regression and the Cox proportional hazards model.
• Catheter duration greater than 48 hours, IV antibiotics, female sex, phlebitis with a previous catheter and catheter material were predictive of phlebitis.
• PEU-Vialon catheters were substantially less phlebitogenic then catheters made of FEP Teflon.
• Vialon cut the risk of all phlebitis cases by 30%. For severe phlebitis, the reduction was 50%.
• A Vialon catheter replaced every 3-4 days, would have up to a 50% lower incidence of phlebitis, than a Teflon catheter changed every 2 days.
• Maki demonstrated that Vialon catheters left in place for 96 hours had no greater risk of phlebitis than using two Teflon catheters. Based on this, he is suggesting a 96-hour protocol when Vialon catheters are used.
  

• Prospective randomized design.
• Independent variable: Cannula type: Teflon® vs Vialon™.
• Dependent variables: Catheter tip deformation, infusion thrombophlebitis.
• Phlebitis measure factored by days individual indwelling.
• Vialon prevents 41-53% of reported phlebitis.
• High incidence of kinking was observed with the Teflon cannulae (29.3%) while none of the Vialon cannulae were kinked.

• Study compared the length of venous dwell time and the rate of IV related complications of Teflon® and Vialon™ peripheral IV catheters.
• Involved 247 catheter insertions.
• Prospective randomized design.
• Vialon acts to prevent 36% of phlebitis compared to Teflon.

• Analysis included survival statistical and multivariate statistical tests.
• Involved 772 catheter insertions.
• Vialon™ reduced the risk of infiltration by 18% relative to the Teflon® material.
• Vialon reduced the risk of infiltration by 35% in the higher risk, low-weight (<1500 g) neonates.
• On average, Vialon remained in situ for 21% longer then Teflon before infiltrating.

• Analysis included survival tests.
• Involved 170 catheter insertions.
• Vialon™ catheters reduced the risk of phlebitis by 49% compared to Teflon® catheters.
• Teflon catheters were found to have significantly more kinking (55.7%) than Vialon catheters (1.7%).

Top of Page